Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development uses normal human cells to enhance brain levels of dopamine, the neurotransmitter deficient in Parkinson’s disease.

2006 Report: Medicines in development for neurological disorders. http://www.phrma.org/files/Neurologic_2006.pdf. Published 2006

Reference

Title
2006 Report: Medicines in development for neurological disorders
Publisher
PhRMA
Publication Date
Published 2006
Authors
PhRMA
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Impact of a 5-Year Delay in Onset on Costs, Americans Age 65 and Older with Alzhemier’s Disease, 2010-2050  
  • Stem Cell Therapy Study Shows Improved Motor Function in Parkinson’s
     
  • Early Gene Therapy Studies Show Promise for Parkinson’s Disease
     
  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • Use of existing or new drugs/compounds for Alzheimer’s prevention could result in a delay of onset of between 2 and 5 years.